Introduction
Salicylic acid (SA) is widely used in topical cosmetic and dermatological consumer products with a long history of safe use (CIR, 2003; Arif, 2015) . As an over the counter topical medication, SA is approved up to 2% (w/w) by the U.S. Food and Drug Administration (US FDA) for treatment of acne (FDA, 1991) . In Europe, SA is listed in the Cosmetics Regulation EC 1223/2009 of the European Union and may be used as preservative in cosmetic products at a maximum concentration of 0.5% (Annex V). For uses other than as preservative, SA may be used in rinseoff hair products at concentrations up to 3%, and in leave-on products at concentrations up to 2% (Annex III). SA is the principal metabolite of acetylsalicylic acid (ASA, aspirin) which is a common analgesic, antipyretic and anti-inflammatory drug with a long history of safe use in humans including use during pregnancy (Herz-Picciotto et al., 1990; Di Sessa et al., 1994; Roberge et al., 2016) .
The US Cosmetic Ingredient Review Expert Panel concluded that the use of topical SA products is safe up to 3% (CIR, 2003) . In addition, SA has been reviewed by the EU Scientific Committee on Cosmetic Products and Non-Food Products intended for consumers (SCCNFP, 2002) who concluded that it was safe for use under the conditions as stated above.
In March 2016, the Committee for Risk Assessment of the European Chemical Agency proposed to classify SA as a Category 2 reproductive toxicant (ECHA, 2016) . The classification is based on adverse developmental effects in two animal species (rat and monkey), which were observed at high oral doses resulting in high SA plasma concentrations (Tanaka et al., 1973a, b; Wilson et al., 1977) . This CMR (carcinogenic, mutagenic, reproductive) hazard classification requires a reassessment of the consumer safety of the currently authorized SA concentrations in topical cosmetic products in Europe.
The conventional safety evaluation of a cosmetic ingredient in
Europe includes a Margin of Safety (MoS) calculation that is determined by dividing the no-observed-adverse-effect level (NOAEL) in mg/kg from a pivotal (usually oral) animal toxicity study by the estimated human systemic dose in mg/kg, usually based on in vitro skin penetration data (SCCS, 2016) . The resulting MoS value should be at least 100-fold to account for inter-and intraspecies differences in toxicokinetics and toxicodynamics. However, especially in the case of extrapolation between different route of administration (e.g. oral vs. dermal) the use of plasma exposures such as area under the plasma concentration-time curve (AUC) or maximum plasma concentration (Cmax) values from animals and humans will considerably strengthen the safety assessment of a cosmetic ingredient. With this approach, a MoS of 25 is considered sufficient since no safety factor for interspecies toxicokinetic differences is required as outlined in the recommendations of the World Health Organization International Programme on Chemical Safety (WHO IPCS, 2005) . The objective of this paper is to present the results of a pharmacokinetic and epidemiologic-based safety assessment of consumer exposure to SA from topical cosmetic products. The MoS calculation is based on the ratio of the SA plasma exposure (Cmax and AUC) at a non-teratogenic dose in animals and humans when compared with estimated human SA systemic plasma Cmax and AUC after dermal exposure to SA-containing cosmetic products. The evaluation of the MoS utilizes data on human plasma exposures following intravenous and oral administration of acetylsalicylic acid (aspirin, ASA), which is rapidly de-acetylated to SA with a half-life of conversion of 13-19.5 min (Costello et al., 1984; Gilman et al., 1990; Navarro et al., 2011) . Therefore, plasma levels of SA provide for an ideal biomarker to quantify and predict not only systemic exposure, but also potential adverse effects of both SA and ASA including potential adverse developmental effects. This approach is supported by the correlation between clinical toxicity of ASA (salicylism) in humans, which occurs at SA plasma levels above 350 μg/mL (Madan and Levitt, 2014) . The risk assessment for teratogenicity also included an evaluation of available epidemiological data on the reproductive safety of oral therapeutic doses of ASA in pregnant women, which shows that the use of ASA at therapeutic doses does not result in adverse pregnancy outcomes (Imperiale and Petrulis, 1991; Schiff and Mashiach, 1992; Shepard, 1986) . By inference, the same conclusion can be applied to SA.
Methods
A step-wise approach (Table 1) was used in this pharmacokineticbased safety assessment to determine the MoS for SA exposure from topical cosmetic products. The approach is comprised of: (1a) an evaluation of effects from SA on the basis of human epidemiological data from oral use of ASA up to the maximum recommended therapeutic dose and (1b) a hazard characterization for SA including animal developmental toxicity studies with ASA and SA used for the definition of no observed adverse effect levels (NOAELs); (2a) an exposure assessment of the SA plasma levels in humans after intravenous and oral application of ASA, as well as after topical applications of SA, and (2b) an aggregate exposure assessment for consumer use of cosmetic products containing SA at the currently authorized concentrations, and (3) a safety assessment including the calculation of a plasma exposurebased margin of safety (MoS), i.e., the ratio of the SA plasma values in humans at a dose without adverse developmental effects and the predicted human exposure level from aggregate exposure to SA via cosmetic products.
Results

3.1.
Step 1A: evaluation of effects based on human epidemiological data on the use of ASA during pregnancy Epidemiological studies (Slone et al., 1976; Shapiro, 1976; Kozer et al., 2002) on the use of ASA also during pregnancy up to the maximum recommended therapeutic dose of 4000 mg/day or 66.7 mg/kg using 60 kg body weight (bw) have demonstrated no evidence of an increased risk of adverse pregnancy outcomes in terms of frequency of stillbirth, neonatal mortality, birth defects or developmental delay. A further meta-analysis of studies on the use of therapeutic low-dose ASA at 50-150 mg/day (Kozer et al., 2003) has demonstrated that this dose range is not associated with any adverse pregnancy outcome, in terms of perinatal mortality, birth complications, congenital malformations or adverse effect on subsequent development. For pregnancies with a moderate or high risk of pre-eclampsia and/or premature delivery, the adverse pregnancy outcome rate was reduced with therapeutic lowdose ASA (50-150 mg/day) and there was no increased risk of early miscarriage with this dose regime (Roberge et al., 2016) . These studies strongly support that neither ASA nor its principal metabolite SA induce adverse developmental effects up to the maximum recommended therapeutic dose in humans, i.e. 4000 mg/day (66.7 mg/kg for a 60 kg person, equivalent to 51 mg/kg SA).
3.2.
Step 1B: hazard characterization of salicylic acid reproductive toxicity in sensitive animal species
The assessment of the teratogenicity of SA was based on oral reproductive toxicity studies with ASA and SA in rats (NOAEL of SA 76.7 mg/kg bw) and monkeys (NOAEL of 100 mg/kg bw). Studies in rabbits were not considered, since the rabbit is considered to be a less sensitive species (NOAEL of 250 mg/kg bw for developmental toxicity) when compared with rat and monkey for adverse developmental effects induced by SA.
Studies in rats
In another developmental toxicity study (Tanaka et al., 1973a) , SA was administered to pregnant Wistar rats at 0, 0.06, 0.1, 0.2 and 0.4% in the diet (equivalent to approximately 30, 50, 100 and 200 mg/ kg bw/day) during GD 8-14. The high dose of 0.4% caused maternal toxicity, high fetal mortality, growth retardation and a high frequency of complex anomalies including cranioschisis, myeloschisis, pes varus, and oligodactyly. At 0.2%, significant fetal growth retardation and a low frequency of anomalies were observed. The NOAELs were established at 0.2% (100 mg/kg bw/day) for maternal toxicity and at 0.1% (50 mg/kg bw/day) for developmental toxicity. A parallel study by oral gavage (Tanaka et al., 1973b) at SA doses of 0, 75, 150 and 300 mg/ kg bw/day gave similar results, which yielded NOAELs of 150 mg/ kg bw/day for maternal toxicity and 75 mg/kg bw/day for developmental toxicity. Table 1 Stepwise approach for a kinetic-based safety assessment of consumer exposure to salicylic acid in topical cosmetic products.
Step 1: Effects evaluation and hazard characterization
Step 2: Exposure assessment
Step 3 Pregnant rats of a Wistar-derived strain received ASA by gavage twice daily at doses of 0, 100, 150 or 200 mg/kg bw during gestation days (GD) 9-12 (Wilson et al., 1977) . At 200 mg/kg bw, maternal toxicity was observed including lethality and body weight loss. At 200 and 150 mg/kg bw, adverse developmental effects included an increased rate of resorptions and malformations, whereas 100 mg/kg bw induced no relevant embryotoxic effects when compared to the control group.
On the basis of these data, the corresponding plasma levels of rats at the NOAEL of 100 mg/kg ASA (equivalent to 76.7 mg/kg SA) are used for the MoS calculations for developmental toxicity of the pharmacokinetic-based safety assessment.
Studies in monkeys
ASA was administered twice daily by gavage to pregnant rhesus monkeys at doses of 100 and 150 mg/kg bw during GD 23-32 (Wilson et al., 1977) . At 150 mg/kg bw (twice daily), malformations such as gross abnormality, cranioshisis and cystic kidney were noted, however embryos were not examined for internal malformations. At 100 mg/kg bw (twice daily) some transitory growth retardation was observed at 32 days post conception, but no teratogenic effects were observed. Thus, the corresponding plasma levels of monkeys after administration of 100 mg/kg (twice daily) are used for the MoS calculations of the pharmacokinetic-based safety assessment.
3.3.
Step 2A: plasma exposure assessment
Metabolism and pharmacokinetics
In humans, SA is well absorbed from the gastrointestinal tract and is rapidly distributed throughout the extracellular fluid and most tissues (Gilman et al., 1990) . In all investigated species, the biotransformation pathways of ASA and SA are the same following initial hydrolysis of ASA to SA. SA is eliminated by renal excretion as an unchanged chemical entity (10%) or after hepatic conjugation with glycine (salicyluric acid 75%), glucuronic acid (salicyl acyl and phenolic glucuronides 5%) and/or after hydroxylation (gentisic acid < 1%) (Gilman et al., 1990; Navarro et al., 2011) . Salicylate elimination is dose-dependent; it appears to be zero order at high concentrations and first order at low concentrations (Levy, 1965; Wientjes and Levy, 1988) . In humans, at low concentrations the elimination processes proceed by first order kinetics with a half-life of 2.9 h; as the dose increases the half-life increases to 22 h (Levy, 1965) . Based upon the relatively low plasma SA levels in humans estimated from topical application of SA-containing cosmetic products the elimination of SA is expected to be linear with a short half-life of approximately 2.9 h.
SA plasma exposures in humans
The data from two independent clinical studies confirm high oral bioavailability of SA when compared to the plasma levels after intravenous (IV) infusion. In a randomized placebo-controlled crossover study (Nagelschmitz et al., 2014) , ASA was administered at 250 and 500 mg IV or orally at 100, 300 or 500 mg to 21 healthy volunteers. In another study (Bochner et al., 1988) , the kinetic profile of a single dose ASA (50 mg) administered orally or IV was studied in 6 healthy volunteers. The same dose given as oral and IV solution resulted in comparable Cmax and AUC values.
To determine the bioavailability of SA after dermal exposure compared to oral administration, 38 female volunteers with either normal, acnegenic, or photodamaged/aged facial skin received repeated (14-day) topical SA applications onto the face (Davis et al., 1997) . The individuals with normal skin were treated with 2% SA in a hydro-alcoholic solution and a cream (moisturizer-like) formulation. The dermal route was compared to oral administration of 81 mg ASA administered once daily for 14 days, i.e., 1.03 mg/kg bw of SA by considering complete hydrolysis of ASA to SA and 60 kg bodyweight. Plasma concentration-time profiles and cumulative urinary excretion of SA were measured after the last dose of 15 consecutive daily topical applications of 27 mg of SA, i.e., 0.45 mg/kg bw (considering 60 kg as body weight). The maximum plasma concentration (Cmax) and area under the curve (AUC) values of SA were determined from blood samples collected within 24 h. The study results suggest that rate and extent of percutaneous absorption of SA were not affected by facial skin condition. Faster rates of absorption (Cmax) were obtained with the hydro-alcoholic formulation when compared with those of the cream formulation. The SA Cmax levels after topical application were about 8 times lower for the cream and 4 times lower for the hydro-alcoholic formulation (corrected for dose) when compared with respective values after oral administration. The AUCs following dermal application were 3-to 2 times lower, respectively, when compared with those following the oral treatment (corrected for dose).
Another two-period crossover study (Fung et al., 2008) was conducted in nine healthy volunteers to compare the relative bioavailability of SA following facial application of a 30% SA-containing hydroalcoholic peel rinse-off formulation (460 mg of SA, i.e., 7.7 mg/kg bw, considering 60 kg bodyweight) applied for 5 min versus an oral dose of 650 mg ASA (i.e., 498 mg SA by assuming 100% of hydrolysis of ASA to SA corresponding to approximately 8.3 mg/kg bw SA). The Cmax, AUC values following dermal application of SA were determined from blood samples collected within 24 h.
The respective pharmacokinetic parameters (C max , AUC t1/2) from the human studies referenced above are summarized in Table 2 .
SA plasma exposures in rats and monkeys
On the basis of the previously described data for rats and monkeys (Tanaka et al., 1973b; Wilson et al., 1977) , the corresponding plasma levels of 100 mg/kg ASA (equivalent to 76.7 mg/kg SA) are used for the margin of safety calculations of the plasma exposure-based safety assessment. The respective pharmacokinetic parameters (C max , AUC) are summarized in Table 3 .
3.4.
Step 2B: plasma exposure from topical use of salicylic acid-containing cosmetic products
Percutaneous absorption
The dermal absorption of SA has been studied in vitro and in vivo both in animals and humans, and the values were strongly dependent on the vehicle or formulation, pH, skin structure, and application conditions on the skin such as application site and occlusion. Absorption from hydro-alcoholic vehicles was greater than that from non-hydro-alcoholic vehicles. In the earlier SCCNFP opinion, a dermal absorption value of 20% from topically applied 2% salicylic acid containing cosmetic formulations was used for the safety assessment (SCCNFP, 2002) . Since then, additional data have become available and the overall review of in vitro and in vivo data reveals dermal absorption values through intact skin in the range between 20 and 50% for in vitro studies and 5.5-70% of the applied dose for in vivo studies, depending on vehicle and species (Mateus et al., 2014; Rubio et al., 2011; Muhammad and Riviere, 2015) . The highest dermal absorption value of approximately 70% was derived from a monkey study (Bucks et al., 1990) . However, the data from this study were not considered adequate for a safety assessment since SA was not tested in a representative cosmetic formulation, but in acetone. Moreover, the number of animals tested was small, the variability of results was high and there was no information in the study description whether the application was under occlusive conditions or not which may have a major impact since acetone is volatile. Hence, for this safety assessment, a dermal absorption value of 50% was used which also corresponds to the default absorption value proposed by the SCCS (SCCS, 2016).
Consumer exposure assessment
The consumer SA exposure levels were calculated using the deterministic exposure assessment as outlined in the SCCS Notes of Guidance (SCCS, 2016) (see Table 4 ). This highly conservative exposure modelling approach assumes that all cosmetic products contain the ingredient at the maximum use concentration and are all used by all persons at a high amount per use, and at a high frequency per day. Moreover, the aggregate exposure is based on the summation of all individual product exposures, thus leading to an 'unrealistic scenario' type calculation. The daily exposure to the different product categories was estimated per the current SCCS Notes of Guidance. The retention factor on the skin is 1 for all products, except for rinse-off products (including shampoo) for which 0.01 is considered. As explained above, a dermal absorption value of 50% was used which also corresponds to the default value proposed by the SCCS. The calculated total daily aggregate systemic exposure from cosmetic products (1.25 mg/kg bw) is used to derive a human plasma level (Cmax, AUC) for SA from the human data after intravenous administration of ASA.
3.5.
Step 3: risk assessment -calculation of the margin of safety based on plasma exposures
The human plasma levels of SA from the estimated cosmetic aggregate daily dermal exposure value of 1.25 mg/kg bw (see Table 4 ) were extrapolated using the data from the available human IV studies with ASA (Bochner et al., 1988; Nagelschmitz et al., 2014) . The plasma values from two IV doses of 0.8 and 4.17 mg/kg bw of ASA (equivalent to 0.61 and 3.2 mg/kg bw SA, respectively) were used in a linear extrapolation analysis to derive the Cmax (Fig. 1A) and AUC values (Fig. 1B) of 7.0 μg/mL and 22 μg x hr/mL, respectively, at the assumed human systemic exposure dose of 1.25 mg/kg bw SA. Fig. 2 shows the estimated MoS values between the Cmax and AUC values (183 μg/mL and 1008 μg x hr/mL, respectively) from epidemiological studies on the clinical use of the daily maximum recommended oral therapeutic dose of ASA (4000 mg, equivalent to 51 mg/kg bw SA) and the topical applications of SA (2% SA, equivalent to 0.45 mg/kg bw SA; 30% SA, equivalent to 7.7 mg/kg bw SA). Fig. 3 shows the MoS values using the respective Cmax and AUC values from the previously described rat and monkey reproductive toxicity studies and the human dermal exposure studies with SA-containing cosmetic products.
In addition, the Cmax and AUC values of the assumed human total aggregate exposure to SA-containing cosmetic products (1.25 mg/ kg bw/day) are 26-and 46-fold, respectively, lower than the maximum oral therapeutic use of ASA.
Discussion
Well documented epidemiological data are available on the clinical use of oral therapeutic doses of ASA. ASA is still used by pregnant women and even clinically prescribed at low doses to prevent preeclampsia (Roberge et al., 2016) and is only contraindicated during the last trimester of pregnancy. The epidemiological studies on the clinical use of the daily maximum recommended oral therapeutic dose of ASA (4000 mg, equivalent to 51 mg/kg bw SA for a 60 kg person) demonstrated no evidence of an increased risk of adverse pregnancy outcomes in terms of frequency of stillbirth, birth defects or developmental delay (Slone et al., 1976; Shapiro, 1976; Kozer et al., 2002 Kozer et al., , 2003 . The estimated SA Cmax and AUC values at the maximum recommended oral ASA dose are 183 μg x hr/mL and 1008 μg/mL, respectively, resulting in safety margins of 25-and 44-fold when compared to the Cmax and AUC values from total aggregate exposure to SA-containing cosmetic products, i.e., 7.0 μg/mL and 22 μg x hr/mL. Nagelschmitz et al. (2014) . e SA data from Davis et al. (1997) . f SA data from Fung et al. (2008) .
g Plasma values used to extrapolate Cmax and AUC for aggregate cosmetic topical exposure used for MOS calculations. The pharmacokinetic-based safety assessment of the risk of teratogenicity described here results in a MoS which strongly supports that salicylic acid-containing cosmetic products are safe for pregnant women. Indeed, for a safety assessment of human exposure to substances, the uncertainty factors usually consider the inter-species and intra-species toxicokinetic and -dynamic variability. When plasma AUC and Cmax values are available from relevant kinetic studies, these values can be directly used for the calculation of the MoS, and uncertainty factors for kinetic variability are no not applied. A MoS of 25 is sufficient to ensure the safety of humans exposed to the substance in question when margins are calculated using animal data; while a MoS of 10 is acceptable when using human epidemiological data (IPCS, 2005) . Thus, the use of SA as cosmetic ingredient at levels currently authorized by the EU cosmetic regulation is safe on the basis of the MoS values above 10 and 25 when ratios are calculated based on safe levels in humans and animals, respectively.
Data from human studies with IV infusion of ASA were used to extrapolate plasma AUC and Cmax values for the estimated total aggregate SA systemic exposure from cosmetic products (1.25 mg/kg/ day). Three studies were identified in the literature where ASA was administered IV (Bochner et al., 1988; Nagelschmitz et al., 2014; Rowland and Riegelman, 1968) . The Rowland and Riegelman, 1968 study was not taken into account because the sensitivity of the method used for ASA detection was considered low and not sufficiently accurate (Bochner et al., 1988) . The Nagelschmitz et al. (2014) study tested a larger number of subjects (N = 21) compared to the Bochner et al. (1988) (N = 6) study, but used higher doses of ASA (250 mg and 500 mg) compared to the low dose of 50 mg ASA administered in the Bochner et al. (1988) study. Given that topical application of SA produces relatively low plasma levels of SA and salicylates follow nonlinear pharmacokinetics at high concentrations, it is more accurate to extrapolate the total aggregate SA exposure from the lower IV doses of ASA. Therefore, the data from the study of Bochner et al. (1988) and the lower dose from the study of Nagelschmitz et al. (2014) were used resulting in Cmax and AUC values of 7.0 μg/mL and 22 μg x hr/mL, respectively ( Fig. 1A and B) . Overall, the studies reveal a similar bioavailability for oral and IV ASA administration. Further, human studies (Davis et al., 1997; Fung et al., 2008) demonstrated that dermal administration SA in different cosmetic formulations resulted in lower plasma levels compared with those after oral administration of ASA. In the Davis et al., 1997 study, two representative SA-containing cosmetic leave-on formulations were applied to human volunteers for 14 days resulting in a topical daily exposure to SA of around 0.45 mg/kg. The Cmax values for the cream and hydro-alcoholic formulations were 10-to 18-fold lower compared to the Cmax value from daily oral intake of 81 mg ASA. Similarly, the AUC Fig. 2 . Margin of safety calculations using salicylic acid plasma levels (Cmax and AUC) from epidemiological studies on the clinical use of the daily maximum recommended oral therapeutic dose of ASA (4000 mg or 66.7 mg/kg bw using 60 kg bw, equivalent to 51 mg/kg bw SA) and the topical application of SA-containing cosmetic products (2% SA equivalent to 0.45 mg/kg bw SA, 30% SA equivalent to 7.7 mg/kg bw SA). Fig. 3 . Margin of Safety calculations using salicylic acid plasma levels (Cmax and AUC) from animal developmental toxicity studies and the topical application of SA-containing cosmetic products.
values for the cream and hydro-alcoholic formulations were 5-to 6-fold lower compared to the AUC value from daily oral intake of 81 mg ASA. In the study of Fung et al. (2008) , a hydro-alcoholic peel rinse-off formulation (applied for 5 min) containing 30% SA (resulting in a topical exposure to SA of around 7.7 mg/kg bw) was compared to oral administration of 650 mg ASA. In this case the Cmax and AUC values were 7-to 53-fold lower than the corresponding values from the oral ASA dose.
Overall, the available human data show that the systemic exposure from dermal exposure to SA-containing cosmetic formulations is considerably less than that after oral intake of ASA up to the daily maximum recommended therapeutic dose of 4000 mg (equivalent to 51 mg/kg bw SA) which is not expected to result in any adverse developmental effects in humans.
Conclusion
The pharmacokinetic and epidemiologic based safety assessment approach outlined in this paper strongly supports the safety of the aggregate exposure to SA-containing cosmetic products at an estimated human systemic exposure dose of 1.25 mg/kg bw/day. The available human data show that the systemic exposure from dermal exposure to SA-containing cosmetic formulations is considerably less than that after oral intake of ASA up to the maximum recommended therapeutic dose of 4000 mg/day (equivalent to 51 mg/kg bw SA) which has not resulted in any evidence for adverse developmental effects in humans. Using both established human safe use levels and no-observed-adverse-effectlevels from animal studies, acceptable safety margins were derived even under worst-case use scenarios (aggregate use). Overall, the use of SA as cosmetic ingredient at levels currently authorized by the EU cosmetic regulation is safe based on the calculated MoS values and clinical evidence with ASA.
